Independent Assessment1. No liquidity
2. Over Compensated Management
3. No designated market maker
4. Inability to partner the Corporations intellectual property
5. No market experience by Directors
6.Massive dilution of the share capital
7.Poorly reported financial position of the Corporation
8. Inability of the Directors to raise capital
9. Inability to advance the Corporations lead therapeutic to clinical trials
The assessment on a cursory examination of Promis Neurosciences is that it cannot be recommended to any new shareholders as the risk is far too high. Management has done a poor job and shareholders have been taken advantage of. Directors compensation proves that your CEO and Chairman are in this to benefit themselves and will blame the market and Covid on their inept management skills. I know your paid pumpers will come out and dispute our assessment, but the proof is in todays announcement, who benefits from this financing? The Directors will take their funds and again be out of cash. If I ever seen a Publically traded Company that needs a shareholder revolt it is this one. A PROXY war should be initiated before they ruin whatever is left. We will sit and watch, good luck shareholders.